Other

Neuren Pharmaceuticals Limited

Neuron Pharmaceuticals Limited

Bickerdike, Mike John

Wen, Jingyuan

Thomas, Gregory Brian

Mike John Bickerdike

Gregory Brian Thomas

Jingyuan Wen

Margaret Anne Brimble

Ernest Stephen Sirimanne

Embodiments of this invention provide methods for therapeutic use of cyclic G-2-allylProline (cG-2-allylP) to treat peripheral neuropathies, including toxin-induced peripheral neuropathy and diabetic peripheral neuropathy as well as manufacture of medicaments including tablets, capsules, and other orally active compositions containing cG-2-allylP, as well as injectable solutions that are useful for treatment of such conditions.

Cyclic glycyl-2-allyl proline and its use in treatment of peripheral neuropathy

Oral formulations of G-2MePE including microemulsions, coarse emulsions, liquid crystals, tablets and encapsulated forms of G-2MePE have improved bioavailability than conventional aqueous formulations. In particular, microparticles, nanoparticles and microemulsions can exhibit great neuroprotective effects after oral administration. In a microemulsion formulation, G-2MePE can nearly completely inhibit cerebral infarction in an animal model of stroke even after the stroke had been initiated. Thus, improved oral formulations can be desirably used to treat a variety of neurodegenerative conditions with improved convenience and improved efficacy.

Oral formulations of glycyl-2-methylprolyl-glutamate

Growing community of inventors

Auckland, New Zealand

Mike John Bickerdike